The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1593
ISSUE1593
March 9, 2020
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
March 9, 2020 (Issue: 1593)
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.